Nicolas Gendron: From HIT to VITT
Nicolas Gendron, Research Fellow, Hematologist at Boston Children’s Hospital, shared a post on LinkedIn:
”From HIT to VITT-like syndromes: an overview of immune thrombocytopenias linked to anti-PF4 antibodies
Very pleased to announce the publication of our synthesis in La Revue du Praticien: “From heparin-induced thrombocytopenia to the emergence of immune thrombotic thrombocytopenia syndromes associated with anti-PF4 antibodies”
This work, carried out with Manon Jouffroy and David Smadja, traces the evolution of knowledge on thrombotic syndromes mediated by anti-PF4 antibodies, from HIT to the emergence of VITT (post-vaccine) and VITT-like (acute “infectious” or chronic, as we recently described in the NEJM Group).
We detail the pathophysiological, diagnostic and therapeutic aspects of these rare but important entities for the understanding of immunothrombosis mediated by anti-PF4 antibodies.”
Read the full article here.
Article: From heparin-induced thrombocytopenia to the emergence of immune thrombotic thrombocytopenia syndromes
Authors: Manon Jouffroy, David M. Smadja, Nicolas Gendron

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
- 
                    Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
 - 
                    Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
 - 
                    Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
 - 
                    Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
 - 
                    Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
 
- 
                    Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
 - 
                    Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
 - 
                    Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
 - 
                    Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
 - 
                    Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
 
- 
                    Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
 - 
                    Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
 - 
                    Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
 - 
                    Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
 - 
                    Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
 
- 
                    Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
 - 
                    Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
 - 
                    Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
 - 
                    Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
 - 
                    Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry
 
